Viracta Therapeutics, Inc.
OTC: VIRX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Craig R. Jalbert
- Employees
- 26
- Headquarters
- Cardiff-by-the-Sea, United States
- IPO year
- 2005
- Market cap
- $388.7K
- Website
- https://www.viracta.com
Loading VIRX…
Loading profile data…Frequently asked questions about VIRX
What does Viracta Therapeutics, Inc. (VIRX) do?
Viracta Therapeutics, Inc. operates as a precision oncology firm, specializing in the development of therapeutic agents aimed at treating cancers linked to viral infections. The company's leading drug candidate, Nana-val (a combination of nanatinostat and valganciclovir), is currently advancing through multiple clinical trials. It is in Phase II...
Where does VIRX trade?
Viracta Therapeutics, Inc. (VIRX) trades on the Other OTC.
What sector is VIRX in?
Viracta Therapeutics, Inc. (VIRX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Viracta Therapeutics, Inc.?
Craig R. Jalbert is the chief executive officer of Viracta Therapeutics, Inc. (VIRX).
Where is Viracta Therapeutics, Inc. headquartered?
Viracta Therapeutics, Inc. is headquartered in United States.
Does VIRX pay a dividend?
Viracta Therapeutics, Inc. (VIRX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did VIRX go public?
Viracta Therapeutics, Inc. (VIRX) completed its initial public offering in 2005.